Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00741897

Enrollment

264

Registered

2008-08-26

Start date

2002-03-31

Completion date

Unknown

Last updated

2009-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis, Allergic, Perennial

Brief summary

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

Interventions

DRUGFexofenadine

Fexofenadine: One 30 mg Tablet once daily for two weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 11 Years

Healthy volunteers

Inclusion criteria

* Children who manifest allergic rhinitis symptoms such as sneezing, rhinorrhea, itchy nose/palate/throat and/or itchy/watery/red eyes.

Design outcomes

Primary

Measure	Time frame
Physician's assessment of symptoms and drug activity (Total symptom scores)	At D 14
Patient's assessment of symptoms and drug activity (Total symptom scores)	At baseline, D 7 and D 14

Secondary

Measure	Time frame
AE and SAE collection	From the signature of the informed consent up to the end of the study

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026